Company: SNSE
Filing Date: 2025-04-01
Form Type: PRE 14A
Source: 0000950170-25-048533
Chunk: 52

Company: Sensei Biotherapeutics, Inc.
Filing Date: 2025-04-01
Form: PRE 14A
Chunk 52
---
 the employees until withdrawn or distributed from the 401(k) plan.

Employment Agreements with our Named Executive Officers

Below are descriptions of our employment agreements with our named executive officers. The agreements generally provide for at-will employment and set forth the named executive officer’s initial base salary, target bonus, eligibility for employee benefits and severance benefits upon a qualifying termination of employment. Furthermore, each of our named executive officers has executed a form of our standard proprietary information and inventions assignment agreement. The key terms of the employment agreements with our named executive officers, including potential payments upon termination or change of control, are described below.

Employment Agreements

Mr. Celebi’s employment agreement became effective upon the closing of our initial public offering. Our employment agreement with Dr. van der Horst was most recently amended and restated effective December 7, 2022 in connection with his appointment as our Chief Scientific Officer. Our employment agreement with Ms. Krebs became effective November 1, 2023 in connection with her appointment as our Chief Business Officer.

The employment agreements provide that, subject to certain conditions and limitations, upon the termination of the employment of an eligible executive officer without Cause or resignation for Good Reason (each, as defined in the employment agreements) not in connection with a Change in Control (as defined in each employment agreement):

| • |     | Mr. Celebi will be eligible to receive continued payment of his base salary for 12 months; Ms. Krebs and Dr. van der Horst will be eligible to receive continued payment of their base salaries for nine months; and |

| • |     | each executive officer shall be eligible to receive COBRA premiums for the applicable length of the severance period as described above. |

In addition, the employment agreements provide that, subject to certain conditions and limitations, upon the termination of the employment of an eligible executive officer without Cause or resignation for Good Reason (each, as defined in the employment agreements) within 12 months following a Change in Control:

| • |     | Mr. Celebi will be eligible to receive a lump-sum cash severance benefit equal to 18 months’ base salary and 150% of his target bonus; Ms. Krebs and Dr. van der Horst will be eligible to receive a lump-sum cash severance benefit equal to 12 months’ base salary and 100% of the officer’s target bonus; |

| • |     | such executive officer shall be eligible to receive COBRA premiums for the applicable length of the sever